Carrier-free nanoprodrug for p53-mutated tumor therapy via concurrent delivery of zinc-manganese dual ions and ROS
Human cancers typically express a high level of tumor-promoting mutant p53 protein (Mutp53) with a minimal level of tumor-suppressing wild-type p53 protein (WTp53). In this regard, inducing Mutp53 degradation while activating WTp53 is a viable strategy for precise anti-tumor therapy. Herein, a new c...
Saved in:
Published in | Bioactive materials Vol. 20; pp. 404 - 417 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
China
Elsevier B.V
01.02.2023
KeAi Publishing KeAi Communications Co., Ltd |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Be the first to leave a comment!